Nasdaq:XENE

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026 14:00 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE)…

1 day ago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:55 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE)…

7 months ago